Project Grant R01AI203541
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $3.4M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $804,464 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research targeting the super elongation complex to regulate HIV transcription and latency. The research addresses HIV persistence in long-lived latent reservoirs that remain a major barrier to functional cure. The project focuses on developing small molecule regulators of viral transcription as...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $251,875 on May 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore the structural basis of antibody-mediated Fc-effector functions in HIV-1 immune complexes. The research establishes a cryo-electron microscopy platform to directly observe how antibodies bound to HIV-1 envelope glycoproteins on virions are recognized by Fc gamma receptors on plasma membrane blebs and...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $3.375 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate viral genetic determinants of HIV transcription control in the context of HIV cure. The project, titled "Viral Genetic Determinants of HIV Transcription Control in the Context of HIV Cure" (R01AI203543), examines how naturally occurring viral...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $3.204 million on June 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the interaction between TAR RNA and INI1/SMARCB1, a component of the BAF chromatin remodeling complex, and its role in HIV-1 transcriptional regulation and latency reactivation. The research examines how INI1's winged helix DNA-binding domain binds to TAR RNA to facilitate...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of convergent RNA polymerase II transcription in HIV-1 latency and reactivation. The research aims to define how convergent POL II transcription—specifically antisense and downstream forms originating from the 5'-LTR—regulates sense HIV-1 transcription...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Medical Branch at Galveston $294,150 on August 1, 2026, for research on defective pro-viruses and viral proteins in neuroHIV and HIV cure strategies under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research employs correlative microscopy (live-cell, confocal, and electron microscopy), mass spectrometry imaging, and spatial proteomic and mRNA analysis to detect, quantify, and...
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institute of Allergy and Infectious Diseases awarded Yale University $751,919 on June 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on transcriptional control of activation-induced deaminase function. This Project Grant (R01AI192485) funds investigation into the molecular mechanisms coordinating activation-induced deaminase (AID)-mediated deamination with RNA polymerase 2 transcription. Understanding these mechanisms is...